Sector: Life Sciences

Latest content

INPI issues update on protection terms for patents covering pharma and non-pharma claimed matter

Patents covering pharmaceutical and non-pharmaceutical related matter will be subject to two distinct terms of protection, according to the latest publication from INPI. Applicants should check whether any pending cases are affected by this change.

13 April 2022

IP transactions in life sciences in ASEAN countries: data export controls

While there are no blanket restrictions on transferring life sciences data outside of ASEAN countries, this must be carried out in compliance with all applicable data protection law or guidelines.

13 April 2022

Recent UK decision in epic Neurim v Mylan patent battle may benefit generics seeking to stay injunctions

The country's courts continue to show great flexibility in an unusual dispute involving insomnia treatment Circadin

08 April 2022

The lessons Big Tech can learn from pharma on inventor diversity

IAM’s Diversity 100 is a listing of the entities with the greatest proportion of female inventors named on US patent grants maintained between 1 January 2010 and 1 January 2022. It is dominated by life sciences companies and is a timely reminder of the importance of targeted and early recruitment, as well as inclusion programmes that genuinely promote parity

06 April 2022

CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side

Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech

04 April 2022

Five key takeaways from IPBC Europe

Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more

02 April 2022

A fairer way to determine royalties in Turkish compulsory licensing

If compulsory licensing is used in Turkey, it is imperative that the individual requirements of each case are considered. This is especially important when it comes to facilitating access to medical treatments for covid-19.

30 March 2022

Bristol-Myers Squibb suit against AstraZeneca may boost hefty immuno-oncology IP revenues

Latest fight over anti-PD-L1 antibodies has high financial stakes

29 March 2022

Fight for covid-19 revenues triggers wave of new mRNA lawsuits

Several new legal actions have been launched by lipid nanoparticle technology owners

28 March 2022

MPEG LA chief calls on rights owners to make CRISPR patent pool a reality

Larry Horn speaks exclusively to IAM about the future of biotech joint licensing programmes

25 March 2022

Unlock unlimited access to all IAM content